Expertise in
2
conditions

Dr. Jessica L. Boklan

Hematology | Oncology
Phoenix Children's
1919 E Thomas Rd, 
Phoenix, AZ 
Clinical Trials:Currently Recruiting for 4 Trials
Expertise in
2
conditions
Phoenix Children's
1919 E Thomas Rd, 
Phoenix, AZ 

Overview

Jessica Boklan is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona.

Dr. Boklan is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Leukemia, Burkitt Lymphoma, Acute Lymphoblastic Leukemia (ALL), Gliomatosis Cerebri, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 24 peer reviewed articles and participating in 60 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in AZ

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Phoenix Children's
1919 E Thomas Rd, Phoenix, AZ 85016

Additional Areas of Focus

Dr. Boklan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

60 Clinical Trials

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Other
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Biological, Drug, Other
Study Drugs: Bleomycin, Bleomycin Sulfate, Carboplatin, Cisplatin, Etoposide, Etoposide Phosphate
Study Phase: Phase 3
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine
Study Phase: Phase 3
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Enrollment Status: Recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Biological, Radiation
Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Study Phase: Phase 3
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
A Phase II Trial of Tisagenlecleucel in First-line High-risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who Are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Biological
Study Drug: CTL019
Study Phase: Phase 2
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
View 6 Less Clinical Trials

24 Total Publications

A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.
A Phase I Study of Carfilzomib with Cyclophosphamide and Etoposide in Relapsed and Refractory Leukemia and Solid Tumors.
Journal: Cancers
Published: July 31, 2025
Similar Doctors
Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Expertise in
32
conditions
Dr. Allison C. Rosenthal
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (13.3 miles away)
480-933-6836
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Allison Rosenthal is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. She has been practicing medicine for over 17 years. Dr. Rosenthal is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
40
conditions
Dr. Craig B. Reeder
Hematology | Oncology
Expertise in
40
conditions
Dr. Craig B. Reeder
Hematology | Oncology
Referral may be required

Mayo Clinic Hospital In Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 (13.3 miles away)
480-342-4800
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Craig Reeder is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Reeder is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Waldenstrom Macroglobulinemia, Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Reeder is currently accepting new patients.

Expertise in
22
conditions
Dr. Saurabh Chhabra
Hematology | Oncology
Expertise in
22
conditions
Dr. Saurabh Chhabra
Hematology | Oncology
Referral may be required

AZ - Cancer

5777 E Mayo Blvd, 
Phoenix, AZ 
 (13.3 miles away)
480-933-6836
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Saurabh Chhabra is a Hematologist and an Oncologist practicing medicine in Phoenix, Arizona. Dr. Chhabra is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Graft Versus Host Disease (GvHD), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Chhabra is currently accepting new patients.

Frequently Asked Questions about Dr. Jessica L. Boklan

How do I make an appointment with Dr. Jessica L. Boklan?

You can book an appointment with Dr. Jessica L. Boklan by calling their office at 602-933-0920. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jessica L. Boklan a top-rated expert for Leukemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jessica L. Boklan is classified as an Advanced expert for Leukemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jessica L. Boklan specialize in?

While Dr. Jessica L. Boklan is a Hematology, they have specific expertise in Leukemia, Burkitt Lymphoma, and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jessica L. Boklan participate in research or clinical trials?

Yes. Dr. Jessica L. Boklan has published 24 articles and abstracts on conditions like Leukemia. You can view a list of Dr. Jessica L. Boklan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jessica L. Boklan accept my insurance?

Dr. Jessica L. Boklan accepts most major insurance plans, including Humana and UnitedHealthcare. We recommend calling the office directly at 602-933-0920 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Boklan's expertise for a condition
ConditionClose
      View All 35 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile